Search

Your search keyword '"Jacobs, Ryan"' showing total 687 results
Start Over Author "Jacobs, Ryan"
687 results on '"Jacobs, Ryan"'

151. Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

Author

Pinilla Ibarz, Javier, primary, Jurczak, Wojciech, additional, Kambhampati, Suman, additional, Lech Maranda, Ewa, additional, Wróbel, Tomasz, additional, Sharman, Jeff P., additional, Zafar, Syed F., additional, Hoffmann, Marc, additional, Huntington, Scott F., additional, Jacobs, Ryan, additional, Bairey, Osnat, additional, Rowland, Chris, additional, Miskin, Hari P., additional, Sportelli, Peter, additional, Weiss, Michael S., additional, O'Connor, Owen A., additional, and Flinn, Ian W., additional

Published
2021
Full Text
View/download PDF

152. Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Author

Jacobs, Ryan, primary, Jurczak, Wojciech, additional, Flinn, Ian W., additional, Grosicki, Sebastian, additional, Giannopoulos, Krzysztof, additional, Wróbel, Tomasz, additional, Zafar, Syed F., additional, Cultrera, Jennifer L., additional, Kambhampati, Suman, additional, Danilov, Alexey V., additional, Burke, John M., additional, Goldschmidt, Jerome, additional, Beach, Douglas F., additional, Huntington, Scott F., additional, Pinilla Ibarz, Javier, additional, Sharman, Jeff P., additional, Siddiqi, Tanya, additional, Brander, Danielle M., additional, Shadman, Mazyar, additional, Pagel, John M., additional, Dlugosz-Danecka, Monika, additional, Ghosh, Nilanjan, additional, Kolibaba, Kathryn S., additional, Sportelli, Peter, additional, Miskin, Hari P., additional, O'Connor, Owen A., additional, Weiss, Michael S., additional, and Gribben, John G., additional

Published
2021
Full Text
View/download PDF

153. First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Author

Ghia, Paolo, primary, Allan, John N., additional, Siddiqi, Tanya, additional, Kipps, Thomas J., additional, Kuss, Bryone J., additional, Opat, Stephen, additional, Flinn, Ian W., additional, Badoux, Xavier C., additional, Tedeschi, Alessandra, additional, Gonzalez-Barca, Eva, additional, Pagel, John M., additional, Jacobs, Ryan, additional, Barrientos, Jacqueline, additional, Szafer-Glusman, Edith, additional, Zhou, Cathy, additional, Ninomoto, Joi, additional, Dean, James P., additional, Tam, Constantine S., additional, and Wierda, William G., additional

Published
2021
Full Text
View/download PDF

154. Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Author

Thompson, Meghan C., primary, Roeker, Lindsey E., additional, Coombs, Catherine C., additional, Jensen, Jeffrey L., additional, Kamdar, Manali, additional, Skarbnik, Alan, additional, Pagel, John M., additional, Bailey, Neil, additional, Pu, Jeffrey J., additional, Jacobs, Ryan, additional, Hill, Brian T., additional, Brander, Danielle M., additional, Shadman, Mazyar, additional, Ujjani, Chaitra S., additional, Battiato, Kristen E., additional, Komari, Celina J., additional, Sacchi De Camargo Correia, Guilherme, additional, Aronson, Julia H., additional, Rhodes, Joanna M, additional, Ghione, Paola, additional, Fakhri, Bita, additional, Barr, Paul M., additional, Portell, Craig A., additional, Lamanna, Nicole, additional, Pinilla-Ibarz, Javier, additional, Zelenetz, Andrew D., additional, Schuster, Stephen J, additional, Allan, John N., additional, Eyre, Toby A., additional, and Mato, Anthony R., additional

Published
2021
Full Text
View/download PDF

155. Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients

Author

Matuszfisher, Ashley, primary, Bose, Rupali, additional, Boselli, Danielle, additional, Magee, Gray, additional, Chen, Tommy, additional, Hu, Bei, additional, Moyo, Tamara K., additional, Soni, Amy, additional, Park, Steven I., additional, Copelan, Edward A., additional, Avalos, Belinda, additional, Symanowski, James T, additional, Raghavan, Derek, additional, Jacobs, Ryan, additional, and Ghosh, Nilanjan, additional

Published
2021
Full Text
View/download PDF

159. Solid-phase epitaxial growth of the correlated-electron transparent conducting oxide SrVO3

Author

Marks, Samuel D., primary, Lin, Lin, additional, Zuo, Peng, additional, Strohbeen, Patrick J., additional, Jacobs, Ryan, additional, Du, Dongxue, additional, Waldvogel, Jason R., additional, Liu, Rui, additional, Savage, Donald E., additional, Booske, John H., additional, Kawasaki, Jason K., additional, Babcock, Susan E., additional, Morgan, Dane, additional, and Evans, Paul G., additional

Published
2021
Full Text
View/download PDF

161. Demonstration of Low Work Function Perovskite SrVO3 Using Thermionic Electron Emission.

Author

Lin, Lin, Jacobs, Ryan, Chen, Dongzheng, Vlahos, Vasilios, Lu‐Steffes, Otto, Alonso, Jose A., Morgan, Dane, and Booske, John

Subjects
*THERMIONIC emission, *ELECTRON emission, *ELECTRON work function, *INDUCTIVE effect, *VACUUM arcs
Abstract

Engineering a material's work function is of central importance for many technologies and in particular electron emitters used in high‐power vacuum electronics and thermionic energy converters. A low work function surface is typically achieved through unstable surface functional species, especially in high power thermionic electron emitter applications. Discovering and engineering new materials with intrinsic, stable low work functions obtainable without volatile surface species would mark a definitive advancement in the design of electron emitters. This work reports evidence for the existence of a low work function surface on a bulk, monolithic, electrically conductive perovskite oxide: SrVO3. After considering the patch field effect on the heterogeneous emitting surface of the bulk polycrystalline samples, this study suggests the presence of low work function (≈2 eV) emissive grains on SrVO3 surface. Emission current densities of 10–100 mA cm–2 at ≈1000 °C, comparable to commercial LaB6 thermionic cathodes, indicative of an overall effective thermionic work function of 2.3–2.7 eV are obtained. This study demonstrates that perovskites like SrVO3 may have intrinsically low work functions comparable to commercialized W‐based dispenser cathodes and suggests that, with further engineering, perovskites may represent a new class of low work function electron emitters. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

163. Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B‐cell lymphoma

Author

Hu, Bei, primary, Boselli, Danielle, additional, Pye, Lisa M., additional, Chen, Tommy, additional, Bose, Rupali, additional, Symanowski, James T., additional, Blackley, Kris, additional, Moyo, Tamara K., additional, Jacobs, Ryan, additional, Park, Steven I., additional, Soni, Amy, additional, Avalos, Belinda R., additional, Copelan, Edward A., additional, Raghavan, Derek, additional, and Ghosh, Nilanjan, additional

Published
2021
Full Text
View/download PDF

168. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.

Author

Ghia, Paolo, primary, Allan, John N., additional, Siddiqi, Tanya, additional, Kipps, Thomas J., additional, Jacobs, Ryan, additional, Opat, Stephen, additional, Barr, Paul M., additional, Tedeschi, Alessandra, additional, Trentin, Livio, additional, Bannerji, Rajat, additional, Jackson, Sharon, additional, Kuss, Byrone, additional, Moreno, Carol, additional, Szafer-Glusman, Edith, additional, Russell, Kristin, additional, Zhou, Cathy, additional, Ninomoto, Joi Suzuki, additional, Dean, James P., additional, Wierda, William G., additional, and Tam, Constantine Si Lun, additional

Published
2021
Full Text
View/download PDF

170. Assessing Correlations of Perovskite Catalytic Performance with Electronic Structure Descriptors

Author

Massachusetts Institute of Technology. Department of Materials Science and Engineering, Jacobs, Ryan, Hwang, Jonathan, Shao-Horn, Yang, Morgan, Dane, Massachusetts Institute of Technology. Department of Materials Science and Engineering, Jacobs, Ryan, Hwang, Jonathan, Shao-Horn, Yang, and Morgan, Dane

Abstract

© 2019 American Chemical Society. Electronic structure descriptors are computationally efficient quantities used to construct qualitative correlations for a variety of properties. In particular, the oxygen p-band center has been used to guide material discovery and fundamental understanding of an array of perovskite compounds for use in catalyzing the oxygen reduction and evolution reactions. However, an assessment of the effectiveness of the oxygen p-band center at predicting key measures of perovskite catalytic activity has not been made and would be highly beneficial to guide future predictions and codify best practices. Here, we have used density functional theory at the Perdew-Burke-Ernzerhof (PBE), PBEsol, PBE + U, strongly constrained and appropriately normed functional, and Heyd-Scuseria-Ernzerhof (HSE06) levels to assess the correlations of numerous measures of catalytic performance for a series of technologically relevant perovskite oxides, using the bulk oxygen p-band center as an electronic structure descriptor. We have analyzed correlations of the calculated oxygen p-band center for all considered functionals with the experimentally measured X-ray emission spectroscopy oxygen p-band center and multiple measures of catalytic activity, including high-temperature oxygen reduction surface exchange rates, aqueous oxygen evolution current densities, and binding energies of oxygen evolution intermediate species. Our results show that the best correlations for all measures of catalytic activity considered here are made with PBE-level calculations, with strong observed linear correlations with the bulk oxygen p-band center (R 2 = 0.81-0.87). This study shows that strong linear correlations between numerous important measures of catalytic activity and the oxygen p-band bulk descriptor can be obtained under a consistent computational framework, and these correlations can serve as a guide for future experiments and simulations for development of perovskite and rela

Published
2021

171. Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Author

Roeker, Lindsey E, Scarfo, Lydia, Chatzikonstantinou, Thomas, Abrisqueta, Pau, Eyre, Toby A., Cordoba, Raul, Muntañola Prat, Ana, Villacampa, Guillermo, Leslie, Lori A., Koropsak, Michael, Quaresmini, Giulia, Allan, John N., Furman, Richard R., Bhavsar, Erica B, Pagel, John M., Hernandez-Rivas, Jose Angel, Patel, Krish, Motta, Marina, Bailey, Neil, Miras, Fatima, Lamanna, Nicole, Alonso, Rosalia, Osorio-Prendes, Santiago, Vitale, Candida, Kamdar, Manali, Baltasar, Patricia, Österborg, Anders, Hanson, Lotta, Baile, Mónica, Rodríguez-Hernández, Ines, Valenciano, Susana, Popov, Viola Maria, Barez Garcia, Abelardo, Alfayate, Ana, Oliveira, Ana C, Eichhorst, Barbara, Quaglia, Francesca M., Reda, Gianluigi, Lopez Jimenez, Javier, Varettoni, Marzia, Marchetti, Monia, Romero, Pilar, Riaza Grau, Rosalía, Munir, Talha, Zabalza, Amaya, Janssens, Ann, Niemann, Carsten U, Perini, Guilherme Fleury, Delgado, Julio, Yanez San Segundo, Lucrecia, Gómez Roncero, Ma Isabel, Wilson, Matthew, Patten, Piers, Marasca, Roberto, Iyengar, Sunil, Seddon, Amanda, Torres, Ana, Ferrari, Angela, Cuéllar-García, Carolina, Wojenski, Daniel, El-Sharkawi, Dima, Itchaki, Gilad, Parry, Helen, Mateos-Mazón, Juan José, Martinez-Calle, Nicolas, Ma, Shuo, Naya, Daniel, Van Der Spek, Ellen, Seymour, Erlene K., Gimeno Vázquez, Eva, Rigolin, Gian Matteo, Mauro, Francesca Romana, Walter, Harriet S, Labrador, Jorge, De Paoli, Lorenzo, Laurenti, Luca, Ruiz, Elena, Levin, Mark-David, Šimkovič, Martin, Špaček, Martin, Andreu, Rafa, Walewska, Renata, Perez-Gonzalez, Sonia, Sundaram, Suchitra, Wiestner, Adrian, Cuesta, Amalia, Broom, Angus, Kater, Arnon P., Muiña, Begoña, Velasquez, César A, Ujjani, Chaitra S., Seri, Cristina, Antic, Darko, Bron, Dominique, Vandenberghe, Elisabeth, Chong, Elise A., Lista, Enrico, García, Fiz Campoy, Del Poeta, Giovanni, Ahn, Inhye, Pu, Jeffrey J., Brown, Jennifer R, Soler Campos, Juan Alfonso, Malerba, Lara, Trentin, Livio, Orsucci, Lorella, Farina, Lucia, Villalon, Lucia, Vidal, Maria Jesus, Sanchez, Maria Jose, Terol, Maria Jose, De Paolis, Maria Rosaria, Gentile, Massimo, Davids, Matthew S., Shadman, Mazyar, Yassin, Mohamed A, Foglietta, Myriam, Jaksic, Ozren, Sportoletti, Paolo, Barr, Paul M., Ramos, Rafael, Santiago, Raquel, Ruchlemer, Rosa, Kersting, Sabina, Huntington, Scott F., Herold, Tobias, Herishanu, Yair, Thompson, Meghan C., Lebowitz, Sonia, Ryan, Christine, Jacobs, Ryan W., Portell, Craig A., Isaac, Krista, Rambaldi, Alessandro, Nabhan, Chadi, Brander, Danielle M., Montserrat, Emili, Rossi, Giuseppe, Garcia-Marco, Jose A., Sr., Coscia, Marta, Malakhov, Nikita, Fernandez-Escalada, Noemi, Skånland, Sigrid Strand, Coombs, Callie C., Ghione, Paola, Schuster, Stephen J., Foà, Robin, Cuneo, Antonio, Bosch, Francesc, Stamatopoulos, Kostas, Ghia, Paolo, Mato, Anthony R., and Patel, Meera

Published
2020
Full Text
View/download PDF

172. Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Author

Gribben, John G., Jurczak, Wojciech, Jacobs, Ryan W., Grosicki, Sebastian, Giannopoulos, Krzysztof, Wrobel, Tomasz, Zafar, Syed F., Cultrera, Jennifer L., Kambhampati, Suman, Danilov, Alexey, Burke, John M., Goldschmidt, Jerome, Beach, Douglas F., Huntington, Scott F., Pinilla Ibarz, Javier, Sharman, Jeff P, Siddiqi, Tanya, Brander, Danielle M., Pagel, John M., Kolibaba, Kathryn S., Dlugosz-Danecka, Monika, Ghosh, Nilanjan, Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A., Weiss, Michael S., and Flinn, Ian W.

Published
2020
Full Text
View/download PDF

175. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation

Author

Sanikommu, Srinivasa Reddy, primary, Reese, Emily S., additional, He, Jiaxian, additional, Lee, Carlos, additional, Ai, Jing, additional, Butler, Candace M., additional, Jacobs, Ryan, additional, Hu, Bei, additional, Atrash, Shebli, additional, Trivedi, Jigar, additional, Bhutani, Manisha, additional, Voorhees, Peter, additional, Usmani, Saad Z., additional, Ghosh, Nilanjan, additional, Fasan, Omotayo, additional, Druhan, Lawrence J., additional, Symanowski, James, additional, Copelan, Edward A., additional, and Avalos, Belinda R., additional

Published
2021
Full Text
View/download PDF

176. The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

Author

Ujjani,Chaitra, Mato,Anthony, Hill,Brian T, Allan,John N, Lansigan,Frederick, Jacobs,Ryan, Skarbnik,Alan, Tuncer,Hande, Pagel,John, Brander,Danielle, Cheson,Bruce, Barr,Paul, Roeker,Lindsey E, Pu,Jeffrey, Shah,Nirav N, Goy,Andre, Schuster,Stephen J, Lamanna,Nicole, Sehgal,Alison, Tam,Constantine S, and Shadman,Mazyar

Subjects
ibrutinib, elderly, Targets and Therapy [Blood and Lymphatic Cancer], CLL, Original Research
Abstract

Chaitra Ujjani, 1 Anthony Mato, 2 Brian T Hill, 3 John N Allan, 4 Frederick Lansigan, 5 Ryan Jacobs, 6 Alan Skarbnik, 7 Hande Tuncer, 8 John Pagel, 9 Danielle Brander, 10 Bruce Cheson, 11 Paul Barr, 12 Lindsey E Roeker, 2 Jeffrey Pu, 13 Nirav N Shah, 14 Andre Goy, 15Stephen J Schuster, 16 Nicole Lamanna, 17 Alison Sehgal, 18 Constantine S Tam, 19 Mazyar Shadman 1 1Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Division of Hematological Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; 4Division of Hematology and Medical Oncology, New York Presbyterian & Weill Cornell, New York, NY, USA; 5Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 6Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA; 7Novant Health Cancer Institute, Charlotte, NC 28204, USA; 8Lowell General Hospital, Tufts Medical Center, Boston, MA, USA; 9Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA; 10Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA; 11Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA; 12Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; 13Division of Hematology/Oncology, SUNY Upstate Medical University, Syracuse, NY, USA; 14Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 15John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; 16Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; 17Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA; 18University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 19Peter McCallum Cancer Centre, University of Melbourne, East Melbourne, VI, AustraliaCorrespondence: Chaitra UjjaniSeattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, 825 Eastlake Ave E, Mail Stop CE3-300, Seattle, WA, USATel +1 206-606-1955Fax +1 206-606-1130Email ujjani@uw.eduIntroduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients > 65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.Keywords: CLL, ibrutinib, elderly

Published
2020

177. CSSI Framework: Machine Learning Materials Innovation Infrastructure (Poster)

Author

Morgan, Dane, Jacobs, Ryan, Voyles, Paul, Ferris, Michael, and Blaiszik, Ben

Abstract

This is a Poster for the NSF CSSI PIs meeting, February 12-13, 2020 in Seattle, WA. The poster describes our project "Machine Learning Innovation Infrastructure", which seeks to support rapid development of machine learning applications in Materials Science and Engineering through (i) easy access to data, (ii) cloud-based tools for application of machine learning, and (iii) support for human and machine accessible and sustainable access to disseminated machine learning models.

Published
2020
Full Text
View/download PDF

178. CSSI Framework: Machine Learning Materials Innovation Infrastructure (Lightning Talk)

Author

Morgan, Dane, Jacobs, Ryan, Voyles, Paul, Ferris, Michael, and Blaiszik, Benjamin J.

Abstract

This is a Lightening Talk for the NSF CSSI PIs meeting, February 12-13, 2020 in Seattle, WA. The talk describes our project "Machine Learning Innovation Infrastructure", which seeks to support rapid development of machine learning applications in Materials Science and Engineering through (i) easy access to data, (ii) cloud-based tools for application of machine learning, and (iii) support for human and machine accessible and sustainable access to disseminated machine learning models.

Published
2020
Full Text
View/download PDF

181. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Author

Wierda, William G., primary, Tam, Constantine S., additional, Allan, John N., additional, Siddiqi, Tanya, additional, Kipps, Thomas J., additional, Opat, Stephen, additional, Tedeschi, Alessandra, additional, Badoux, Xavier C., additional, Kuss, Bryone J., additional, Jackson, Sharon, additional, Moreno, Carol, additional, Jacobs, Ryan, additional, Pagel, John M., additional, Flinn, Ian W., additional, Zhou, Cathy, additional, Szafer-Glusman, Edith, additional, Ninomoto, Joi, additional, Dean, James P., additional, James, Danelle F., additional, and Ghia, Paolo, additional

Published
2020
Full Text
View/download PDF

182. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B‐cell lymphoma, leg type.

Author

Moore, Donald C., Soni, Amy C., Hu, Bei, Smith, Elton T., Levine, Jonathan, Moyo, Tamara K., Jacobs, Ryan, Ghosh, Nilanjan, and Park, Steven I.

Subjects
DIFFUSE large B-cell lymphomas, LENALIDOMIDE, RITUXIMAB, MYELOID differentiation factor 88
Abstract

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is an exceedingly rare extra-nodal variant of diffuse large B-cell lymphoma (DLBCL) with an aggressive natural history that often manifests as red cutaneous tumour lesions on the lower extremities. Additionally, with the chemoresistant nature of PCDLBCL-LT and the relatively poor prognosis, many patients experience disease relapse and thus, novel treatment paradigms are needed for salvage therapy. PET/CT 13 months after starting therapy shows continued CR, and the patient remains in remission clinically at 20 months. After four cycles of therapy, an interim PET/CT scan demonstrated a CR with no hypermetabolic uptake to indicate active, recurrent, or metastatic disease. [Extracted from the article]

Published
2022
Full Text
View/download PDF

186. Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Author

Mato, Anthony R., primary, Roeker, Lindsey E., additional, Lamanna, Nicole, additional, Allan, John N., additional, Leslie, Lori, additional, Pagel, John M., additional, Patel, Krish, additional, Osterborg, Anders, additional, Wojenski, Daniel, additional, Kamdar, Manali, additional, Huntington, Scott F., additional, Davids, Matthew S., additional, Brown, Jennifer R., additional, Antic, Darko, additional, Jacobs, Ryan, additional, Ahn, Inhye E., additional, Pu, Jeffrey, additional, Isaac, Krista M., additional, Barr, Paul M., additional, Ujjani, Chaitra S., additional, Geyer, Mark B., additional, Berman, Ellin, additional, Zelenetz, Andrew D., additional, Malakhov, Nikita, additional, Furman, Richard R., additional, Koropsak, Michael, additional, Bailey, Neil, additional, Hanson, Lotta, additional, Perini, Guilherme F., additional, Ma, Shuo, additional, Ryan, Christine E., additional, Wiestner, Adrian, additional, Portell, Craig A., additional, Shadman, Mazyar, additional, Chong, Elise A., additional, Brander, Danielle M., additional, Sundaram, Suchitra, additional, Seddon, Amanda N., additional, Seymour, Erlene, additional, Patel, Meera, additional, Martinez-Calle, Nicolas, additional, Munir, Talha, additional, Walewska, Renata, additional, Broom, Angus, additional, Walter, Harriet, additional, El-Sharkawi, Dima, additional, Parry, Helen, additional, Wilson, Matthew R., additional, Patten, Piers E. M., additional, Hernández-Rivas, José-Ángel, additional, Miras, Fatima, additional, Fernández Escalada, Noemi, additional, Ghione, Paola, additional, Nabhan, Chadi, additional, Lebowitz, Sonia, additional, Bhavsar, Erica, additional, López-Jiménez, Javier, additional, Naya, Daniel, additional, Garcia-Marco, Jose Antonio, additional, Skånland, Sigrid S., additional, Cordoba, Raul, additional, and Eyre, Toby A., additional

Published
2020
Full Text
View/download PDF

191. Outcomes in minority patients (pt) with aggressive B cell lymphoma (BCL) if optimally managed with equal access to care and nurse navigation (NN).

Author

Hu, Bei, primary, Chen, Tommy, additional, Boselli, Danielle, additional, Pye, Lisa, additional, Bose, Rupali, additional, Raghavan, Derek, additional, Symanowski, James Thomas, additional, Blackley, Kris, additional, Moyo, Tamara Kay, additional, Jacobs, Ryan, additional, Park, Steven, additional, Soni, Amy, additional, Avalos, Belinda, additional, Copelan, Edward Alan, additional, and Ghosh, Nilanjan, additional

Published
2020
Full Text
View/download PDF

195. Effect of Nonuniform Emission on Miram Curves

Author

Chernin, David, primary, Lau, Y. Y., additional, Petillo, John J., additional, Ovtchinnikov, Serguei, additional, Chen, Dongzheng, additional, Jassem, Abhijit, additional, Jacobs, Ryan, additional, Morgan, Dane, additional, and Booske, John H., additional

Published
2020
Full Text
View/download PDF

199. Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Author

Mato, Anthony R., primary, Roeker, Lindsey E., primary, Eyre, Toby A., primary, Jacobs, Ryan, primary, Hill, Brian T., primary, Lamanna, Nicole, primary, Brander, Danielle M., primary, Shadman, Mazyar, primary, Ujjani, Chaitra, primary, Yazdy, Maryam, primary, Perini, Guilherme Fleury, primary, Pinilla Ibarz, Javier, primary, Barrientos, Jacqueline C, primary, Skarbnik, Alan, primary, Torka, Pallawi, primary, Pu, Jeffrey J, primary, Pagel, John M., primary, Gohil, Satyen, primary, Fakhri, Bita, primary, Choi, Michael Y., primary, Coombs, Catherine C., primary, Rhodes, Joanna, primary, Barr, Paul M., primary, Portell, Craig A., primary, Parry, Helen, primary, Garcia, Christine Ann, primary, Whitaker, Kate J, primary, Winter, Allison M., primary, Sitlinger, Andrea, primary, Khajavian, Sirin, primary, Grajales-Cruz, Ariel F, primary, Isaac, Krista, primary, Shah, Pratik, primary, Akhtar, Othman S., primary, Pocock, Rachael, primary, Lam, Kentson, primary, Voorhees, Timothy J, primary, Schuster, Stephen J., primary, Rodgers, Thomas David, primary, Martinez-Calle, Nicolas, primary, Munir, Talha, primary, Bhavsar, Erica B, primary, Bailey, Neil, primary, Lee, Jason C., primary, Weissbrot, Hanna, primary, Nabhan, Chadi, primary, Goodfriend, Julie, primary, King, Amber C., primary, Zelenetz, Andrew D., primary, Dorsey, Colleen, primary, Bigelow, Kayla, primary, Cheson, Bruce D., primary, Fox, Christopher P, primary, and Allan, John N., primary

Published
2019
Full Text
View/download PDF

200. Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

Author

Yazdy, Maryam Sarraf, primary, Mato, Anthony R., additional, Roeker, Lindsey E., additional, Jarral, Umair, additional, Ujjani, Chaitra S., additional, Shadman, Mazyar, additional, Skarbnik, Alan, additional, Whitaker, Kate J, additional, Deonarine, Isaac, additional, Kabel, Charlene C., additional, Stump, Sarah E., additional, Goodfriend, Julie, additional, Pagel, John M., additional, Bailey, Neil, additional, Patel, Krish, additional, Jacobs, Ryan, additional, Feldman, Tatyana A., additional, Leslie, Lori A., additional, Goy, Andre, additional, Coombs, Catherine C., additional, Muluneh, Benyam, additional, Khajavian, Sirin, additional, Lamanna, Nicole, additional, Weissbrot, Hanna, additional, Weiss, Jessica, additional, and Cheson, Bruce D., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results